Zacks: Analysts Expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to Announce -$0.45 EPS
Wall Street brokerages expect that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will post earnings of ($0.45) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.47) and the highest is ($0.43). Lexicon Pharmaceuticals posted earnings of ($0.37) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 21.6%. The business is expected to announce its next quarterly earnings results before the market opens on Tuesday, August 1st.
On average, analysts expect that Lexicon Pharmaceuticals will report full year earnings of ($1.48) per share for the current financial year, with EPS estimates ranging from ($1.57) to ($1.39). For the next year, analysts anticipate that the firm will post earnings of ($0.80) per share, with EPS estimates ranging from ($1.15) to ($0.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Lexicon Pharmaceuticals.
LXRX has been the topic of several research reports. HC Wainwright set a $27.00 price objective on shares of Lexicon Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a report on Wednesday, April 5th. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 5th. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Finally, ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $26.67.
A number of institutional investors have recently added to or reduced their stakes in the company. C WorldWide Group Holding A S raised its position in Lexicon Pharmaceuticals by 2.5% in the first quarter. C WorldWide Group Holding A S now owns 11,677 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 280 shares in the last quarter. 361 Capital LLC purchased a new position in Lexicon Pharmaceuticals during the first quarter valued at about $186,000. Trexquant Investment LP purchased a new position in Lexicon Pharmaceuticals during the first quarter valued at about $323,000. Principal Financial Group Inc. raised its position in Lexicon Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 22,684 shares of the biopharmaceutical company’s stock valued at $325,000 after buying an additional 70 shares in the last quarter. Finally, American International Group Inc. raised its position in Lexicon Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 26,020 shares of the biopharmaceutical company’s stock valued at $373,000 after buying an additional 1,716 shares in the last quarter.
Lexicon Pharmaceuticals (NASDAQ LXRX) traded up 0.60% during mid-day trading on Wednesday, hitting $16.89. The company had a trading volume of 169,215 shares. The company has a 50 day moving average of $16.45 and a 200 day moving average of $15.30. Lexicon Pharmaceuticals has a 1-year low of $13.41 and a 1-year high of $19.62. The firm’s market capitalization is $1.78 billion.
TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to Announce -$0.45 EPS” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/26/zacks-analysts-expect-lexicon-pharmaceuticals-inc-nasdaqlxrx-to-announce-0-45-eps.html.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.